Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-lowering therapies in development.

Anthony S Wierzbicki1

  • 1St. Thomas' Hospital, Department of Chemical Pathology, Lambeth Palace Road, London, SE1 7EH, UK. Anthony.Wierzbicki@kcl.ac.uk

Expert Opinion on Investigational Drugs
|October 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Metabolic Management of Adult Refsum Disease: Guidance From the Medical and Scientific Committee of Global DARE (Defeat Adult Refsum Everywhere).

Journal of inherited metabolic disease·2026
Same author

Adult Refsum Disease: Case Series of Reducing Circulating Phytanic Acid Levels With Dietary Interventions.

JIMD reports·2026
Same author

Dopaminergic modulation of pancreatic beta-cell insulin secretion and implications for antipsychotic-induced glucose dysregulation: a systematic review and meta-analysis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Systematic identification of familial hypercholesterolaemia: An updated systematic review and meta-analysis.

Atherosclerosis·2026
Same author

<i>Ex vivo</i> expanded human regulatory T cells promote cholesterol efflux and PON1 expression in oxLDL-exposed macrophages via gap junction-mediated cAMP transfer.

Frontiers in immunology·2025
Same author

Rare variant genetic landscape of familial chylomicronemia syndrome (FCS) in the United Kingdom.

Genetics in medicine open·2025
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Novel lipid-lowering therapies are emerging for atherosclerosis treatment. These new agents, including combination therapies, aim for improved efficacy and tolerability over existing treatments.

Area of Science:

  • Cardiovascular Pharmacology
  • Atherosclerosis Therapeutics
  • Lipid Metabolism

Background:

  • Lipid-lowering interventions are crucial for managing atherosclerosis and its complications.
  • Established therapies include statins, bile acid sequestrants, nicotinic acid, and fibrates.

Purpose of the Study:

  • To summarize novel and emerging lipid-altering therapies for atherosclerosis.
  • To highlight potential combination therapies and new drug classes in development.

Main Methods:

  • Review of novel lipid-altering drug classes that have reached at least animal model trials.
  • Includes squalene synthase inhibitors, microsomal transfer protein inhibitors, and others.

Main Results:

  • Several novel lipid-altering therapies are under development, including combination approaches.

Related Experiment Videos

  • These agents target various pathways in lipid metabolism and inflammation.

    • Conclusions:

    • Lipid-altering drug development is a rapidly advancing field with potential synergistic treatments.
    • New agents must demonstrate superior efficacy or tolerability and undergo clinical endpoint trials.